



AFRICAN VACCINE MANUFACTURING INITIATIVE

Annual General Meeting

AGENDA

Cape Town, South Africa

30 November 2016 – 01 December 2016

Venue Location: Southern Sun Newlands

Day 1: 30 November 2016

AFRICAN HEALTH

DISEASES OF IMPORTANCE

EBOLA VIRUS DISEASE VACCINES

STATUS OF EBOLA VACCINES TRIALS

Vaccine	Organizations	Status
Chimp adenovirus 3 vectored glycoprotein (cAd3-EBO Z)	GSK&NIAID	Phase III Feb. 2016
rVSV vectored glycoprotein (VSV-EBOV)	Newlink Genetics & Merck	in use (flare ups/ West Africa)
Human adenovirus 5 vectored 2014 glycoprotein insert	BIT & CanSino	Phase I complete
Adenovirus 26 vectored glycoprotein / MVA-BN (Ad26.ZEBOV/ MVA-BN)	Johnson & Johnson	Phase I complete April, 2016
HPIV-3 vectored glycoprotein	Ministry of Health (Russia)	Phase I planned

STATUS OF EBOLA VACCINES TRIALS

Vaccine	Organization	Status
Rabies vectored glycoprotein	T. Jefferson & NIAID	Non-human primate challenge complete
Purified glycoprotein	Protein Sciences	NHP challenge initiated
Ebola ΔVP30 H₂O₂ treated	University of Wisconsin	Non-human primate challenge complete

OTHER EBOLA VACCINES IN PIPELINE

Ebola GP vaccine

A glycoprotein (GP) nanoparticle (EBOV GP) vaccine - Novavax Inc

**Based on 2014 Guinea EBV strain in animal studies, with EBOV GP
Induced immune response, enhanced X10-x100 fold with adjuvant**

Nasal vaccine

**A nasal spray Ebola vaccine being developed by research team at
the Univ. of Texas-Austin**

Vaxart tablet

**A temperature-stable tablet is being developed by Vaxart Inc, - reduced
cold-chain requirement; phase 1 trial in planning stage**

OTHER EBOLA VACCINES IN PIPELINE

Novel recombinant adenovirus type-5 vector-based Ebola vaccine, derived from 2014 EV GP in a double-blind, randomized Phase 1 trial, conducted in China – efficacy with no significant safety concerns

Whole virus vaccine

NHP vaccinated with a strain of Ebola- EBOV Δ VP30, which is unable to replicate. Animals developed some measure of protection

WHAT IS AFRICA DOING?

U.S. national stockpile

U.S. government will eventually provide over \$1 billion in contracts to companies to develop medicine and vaccines for Ebola virus disease.

GAVI

(a) US\$ 300 million allocated to the production and procurement of up to 12 million courses of first-generation Ebola vaccines

(b). US\$ 45 million allocated to fund an Ebola vaccine roll-out

(c) US\$ 45 million allocated to support recovery of health systems in EVD affected countries

ON PREPAREDNESS – SHOULD EBOLA COME BACK...

AFRICA SAYS ..CHECK WITH THE DONORS & PARTNERS

**ON PREPAREDNESS – SHOULD EBOLA COME BACK...
AFRICA SAYS ..CHECK WITH THE DONORS & PARTNERS,
BECAUSE ..MANY PROBLEMS OVERWHELM US**



The 15 Richest People in South Africa and the Secret Behind Their Wealth

By [stephanie](#) on May 17, 2016
Advertisement

South Africa has become one of the most stable and fastest developing countries on the African continent.

Markus Jooste

\$400 Million

